Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: Potential risk of diminished sunitinib bioavailability

Journal of Molecular Medicine

Volumn 89, Issue 6, 2011, Pages 595-602

  Ge, Jun ^a   Tan, Ben Xu ^a   Chen, Ye ^a   Yang, Li ^a   Peng, Xing Chen ^a   Li, Hong Ze ^a   Lin, Hong Jun ^a   Zhao, Yu ^a   Wei, Meng ^a   Cheng, Ke ^a   Li, Long Hao ^a   Dong, Hang ^a   Gao, Feng ^a   He, Jian Ping ^a   Wu, Yang ^a   Qiu, Meng ^a   Zhao, Ying Lan ^a   Su, Jing Mei ^a   Hou, Jian Mei ^a   Liu, Ji Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bioavailability; Epigallocatechin 3 gallate; Green tea polyphenol; Sunitinib

Indexed keywords

EPIGALLOCATECHIN GALLATE; POLYPHENOL; SUNITINIB;

ACIDITY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRECIPITATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STATISTICAL SIGNIFICANCE; TEA;

ANIMALS; BIOLOGICAL AVAILABILITY; CATECHIN; CHEMICAL PRECIPITATION; HERB-DRUG INTERACTIONS; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; TEA;

EID: 79959925166     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0737-3     Document Type: Article

References (29)

1. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 10.1016/S0140-6736(06)69446-4 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL (Pubitemid 44528723)
2. VL Goodman EP Rock R Dagher RP Ramchandani S Abraham JV Gobburu BP Booth SL Verbois DE Morse CY Liang N Chidambaram JX Jiang S Tang K Mahjoob R Justice R Pazdur 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 1367 1373 10.1158/1078-0432.CCR-06-2328 17332278 10.1158/1078-0432.CCR-06-2328 1:CAS:528:DC%2BD2sXitlSjsbc%3D (Pubitemid 46450424)
3. RJ Motzer BI Rini RM Bukowski BD Curti DJ George GR Hudes BG Redman KA Margolin JR Merchan G Wilding MS Ginsberg J Bacik ST Kim CM Baum MD Michaelson 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 10.1001/jama.295.21.2516 16757724 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D (Pubitemid 43854967)
4. JJ Shah DJ Kuhn RZ Orlowski 2009 Bortezomib and EGCG: no green tea for you? Blood 113 5695 5696 10.1182/blood-2009-03-204776 19498025 10.1182/blood-2009-03-204776 1:CAS:528:DC%2BD1MXnsVSks7w%3D
5. EB Golden PY Lam A Kardosh KJ Gaffney E Cadenas SG Louie NA Petasis TC Chen AH Schonthal 2009 Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors Blood 113 5927 5937 10.1182/blood-2008-07-171389 19190249 10.1182/blood-2008-07-171389 1:CAS:528:DC%2BD1MXnsVSktro%3D
6. S Kuriyama T Shimazu K Ohmori N Kikuchi N Nakaya Y Nishino Y Tsubono I Tsuji 2006 Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study JAMA 296 1255 1265 10.1001/jama.296.10.1255 16968850 10.1001/jama.296.10.1255 1:CAS:528: DC%2BD28Xps1GmsL8%3D (Pubitemid 44394897)
7. N Khan F Afaq M Saleem N Ahmad H Mukhtar 2006 Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate Cancer Res 66 2500 2505 10.1158/0008-5472.CAN-05-3636 16510563 10.1158/0008-5472.CAN- 05-3636 1:CAS:528:DC%2BD28XhvV2htrc%3D
8. Silverstein RM, Webster FX, Kiemle D (2005) Spectrometric identification of organic compounds [M]. Wiley, Texas, pp 25-80
9. N Said K Motamed 2005 Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis Am J Pathol 167 1739 1752 16314484 10.1016/S0002-9440(10)61255-2 1:CAS:528: DC%2BD28Xkt1aqsw%3D%3D (Pubitemid 41713324)
10. WS Kamoun CD Ley CT Farrar AM Duyverman J Lahdenranta DA Lacorre TT Batchelor E di Tomaso DG Duda LL Munn D Fukumura AG Sorensen RK Jain 2009 Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 2542 2552 10.1200/JCO.2008.19.9356 19332720 10.1200/JCO.2008.19.9356 1:CAS:528:DC%2BD1MXmvVOhsbY%3D
11. TH Kang JH Lee CK Song HD Han BC Shin SI Pai CF Hung C Trimble JS Lim TW Kim TC Wu 2007 Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination Cancer Res 67 802 811 10.1158/0008-5472.CAN-06-2638 17234792 10.1158/0008-5472.CAN-06-2638 1:CAS:528:DC%2BD2sXmtVKqug%3D%3D (Pubitemid 46192221)
12. ZY Wang R Agarwal DR Bickers H Mukhtar 1991 Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols Carcinogenesis 12 1527 1530 1860173 10.1093/carcin/12.8.1527 1:CAS:528:DyaK3MXlslyhsbc%3D
13. VM Adhami A Malik N Zaman S Sarfaraz IA Siddiqui DN Syed F Afaq FS Pasha M Saleem H Mukhtar 2007 Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo Clin Cancer Res 13 1611 1619 10.1158/1078-0432.CCR-06-2269 17332308 10.1158/1078-0432.CCR-06-2269 1:CAS:528:DC%2BD2sXitlSjtb4%3D (Pubitemid 46450454)
14. D Umeda S Yano K Yamada H Tachibana 2008 Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor J Biol Chem 283 3050 3058 10.1074/jbc.M707892200 18079119 10.1074/jbc.M707892200 1:CAS:528:DC%2BD1cXhtlyjs7Y%3D
15. VM Adhami IA Siddiqui N Ahmad S Gupta H Mukhtar 2004 Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer Cancer Res 64 8715 8722 10.1158/0008-5472.CAN-04-2840 15574782 10.1158/0008-5472.CAN-04-2840 1:CAS:528:DC%2BD2cXhtVCjs7rE (Pubitemid 39552088)
16. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss JO Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D (Pubitemid 36109749)
17. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie KW Yee LM Wong W Hong LB Lee A Town BD Smolich WC Manning LJ Murray MC Heinrich JM Cherrington 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605 10.1182/blood-2002-07-23072002-07-2307 12531805 10.1182/blood-2002-07-2307 (Pubitemid 36857948)
18. EP Rock V Goodman JX Jiang K Mahjoob SL Verbois D Morse R Dagher R Justice R Pazdur 2007 Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist 12 107 113 10.1634/theoncologist.12-1- 107 17227905 10.1634/theoncologist.12-1-107 1:CAS:528:DC%2BD2sXhvVaksro%3D (Pubitemid 46143508)
19. S Mirkov BJ Komoroski J Ramirez AY Graber MJ Ratain SC Strom F Innocenti 2007 Effects of green tea compounds on irinotecan metabolism Drug Metab Dispos 35 228 233 10.1124/dmd.106.012047 17108060 10.1124/dmd.106.012047 1:CAS:528:DC%2BD2sXhvVKrs7o%3D (Pubitemid 46148734)
20. HH Chow IA Hakim DR Vining JA Crowell CA Cordova WM Chew MJ Xu CH Hsu J Ranger-Moore DS Alberts 2006 Effects of repeated green tea catechin administration on human cytochrome P450 activity Cancer Epidemiol Biomark Prev 15 2473 2476 10.1158/1055-9965.EPI-06-0365 10.1158/1055-9965.EPI-06-0365 1:CAS:528:DC%2BD28XhtlCrtrvK (Pubitemid 46048307)
21. G Springsteen BH Wang 2002 A detailed examination of boronic acid-diol complexation Tetrahedron 58 5291 5300 10.1016/S0040-4020(02)00489-1 1:CAS:528:DC%2BD38XkvVWktLs%3D (Pubitemid 34663811)
22. AS Tsao D Liu J Martin XM Tang JJ Lee AK El-Naggar I Wistuba KS Culotta L Mao A Gillenwater YM Sagesaka WK Hong V Papadimitrakopoulou 2009 Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions Cancer Prev Res (Phila) 2 931 941 10.1158/1940-6207.CAPR-09-0121 10.1158/1940-6207.CAPR-09-0121 1:CAS:528:DC%2BC3cXptVyrsbs%3D
23. X Zhang H Zhang M Tighiouart JE Lee HJ Shin FR Khuri CS Yang ZG Chen DM Shin 2008 Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor Int J Cancer 123 1005 1014 10.1002/ijc.23585 18546267 10.1002/ijc.23585 1:CAS:528: DC%2BD1cXhtVSrsLvP
24. MR Sartippour R Pietras DC Marquez-Garban HW Chen D Heber SM Henning G Sartippour L Zhang M Lu O Weinberg JY Rao MN Brooks 2006 The combination of green tea and tamoxifen is effective against breast cancer Carcinogenesis 27 2424 2433 10.1093/carcin/bgl066 16785249 10.1093/carcin/bgl066 1:CAS:528:DC%2BD28Xht1OgsrnE (Pubitemid 44884099)
25. MA Shammas P Neri H Koley RB Batchu RC Bertheau V Munshi R Prabhala M Fulciniti YT Tai SP Treon RK Goyal KC Anderson NC Munshi 2006 Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications Blood 108 2804 2810 10.1182/blood-2006-05-022814 16809610 10.1182/blood-2006-05-022814 1:CAS:528:DC%2BD28XhtFWgtL3M
26. G Sonpavde PO Periman D Bernold D Weckstein MT Fleming MD Galsky WR Berry F Zhan KA Boehm L Asmar TE Hutson 2010 Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 319 324 10.1093/annonc/mdp323 19633050 10.1093/annonc/mdp323 1:STN:280:DC%2BC3c%2Fls1emsQ%3D%3D
27. DJ Gallagher MI Milowsky SR Gerst N Ishill J Riches A Regazzi MG Boyle A Trout AM Flaherty DF Bajorin 2010 Phase II study of sunitinib in patients with metastatic urothelial cancer J Clin Oncol 28 1373 1379 10.1200/JCO.2009.25.3922 20142593 10.1200/JCO.2009.25.3922 1:CAS:528:DC%2BC3cXksFSqurw%3D
28. S Novello GV Scagliotti R Rosell MA Socinski J Brahmer J Atkins C Pallares R Burgess L Tye P Selaru E Wang R Chao R Govindan 2009 Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer Br J Cancer 101 1543 1548 10.1038/sj.bjc.6605346 19826424 10.1038/sj.bjc.6605346 1:CAS:528: DC%2BD1MXhtlWmu7fF
29. BI Rini JA Garcia MM Cooney P Elson A Tyler K Beatty J Bokar T Mekhail RM Bukowski GT Budd P Triozzi E Borden P Ivy HX Chen A Dolwati R Dreicer 2009 A phase I study of sunitinib plus bevacizumab in advanced solid tumors Clin Cancer Res 15 6277 6283 10.1158/1078-0432.CCR-09-0717 19773375 10.1158/1078-0432.CCR- 09-0717 1:CAS:528:DC%2BD1MXhtF2lurjF